Physician profile
Boris Sagalovsky
NPI 1073510087
$6,086.53
in general payments reported to CMS, 2019-2025
28 companies · $13.98 in 2025
The $13.98 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $325 · 2021: $2,099 · 2022: $845 · 2023: $443 · 2024: $120 · 2025: $13.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,283.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $960.87 | 2019-2023 | |
| Philips North America LLC | $887.75 | 2019 | |
| Inari Medical, INC. | $568.10 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $363.93 | 2019-2023 | Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.68 | 2019-2023 | Jardiance |
| Medtronic, INC. | $202.68 | 2021-2024 | Hawkone, Concertotm, Abre |
| Janssen Pharmaceuticals, INC | $200.54 | 2019-2020 | |
| Abbott Laboratories | $197.18 | 2021-2023 | Perclose Prostyle |
| Cardiovascular Systems INC. | $142.68 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.94 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.23 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $124.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.40 | 2020 | |
| Celgene Corporation | $103.35 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.64 | 2019 | |
| Bard Peripheral Vascular, INC. | $58.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.59 | 2019 | |
| Chiesi USA, INC. | $40.12 | 2019-2020 | |
| Amgen INC. | $36.86 | 2019-2020 | |
| Cardiva Medical, INC. | $34.08 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Lundbeck LLC | $31.54 | 2019 | |
| Abiomed | $22.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.80 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.33 | 2019 | |
| Cordis US Corp. | $13.98 | 2025 | |
| Medtronic Vascular, INC. | $12.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Sagalovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.